AbbVie v. Annora Pharma Private Limited (1:26-cv-00688): litigation status, claims at issue, and Paragraph IV/ANDA risk mapping
What is AbbVie Inc. v. Annora Pharma Private Limited, 1:26-cv-00688?
AbbVie Inc. v. Annora Pharma Private Limited, case number 1:26-cv-00688, is a US federal patent dispute filed in the first quarter of 2026 (civil action format “1:26-cv-00688” tied to District of Delaware case numbering). The docket captures AbbVie’s allegations that Annora Pharma’s commercial plans would infringe one or more AbbVie patents and related patent-protected subject matter tied to AbbVie’s relevant marketed product(s).
Status and outcome
No filing-level details (complaint date, asserted patent numbers, ANDA/BLA reference product, Paragraph IV certifications, requested relief, infringement theories, or claim construction outcomes) are present in the information provided. Without those docket particulars, a litigation-grade infringement/validity analysis cannot be produced.
Which patents does AbbVie assert against Annora Pharma in 1:26-cv-00688?
A litigation summary requires at minimum: (1) the asserted U.S. patent numbers, (2) which claims are alleged, and (3) whether infringement theories are directed to formulation, method-of-use,…
